Webinar: Alpha-Synuclein Seed Amplification Assays in Neurodegenerative Research by StressMarq
This webinar provides an introduction to the scientific foundation, clinical relevance and future directions of alpha-synuclein seed amplification assays (SAA / RT-QuIC). Dr Parkkinen will share her expertise in neuropathology and discuss how these assays contribute to research on neurodegenerative conditions.
Online
Join the upcoming webinar to gain insights into the scientific foundation, clinical relevance and future directions of alpha-synuclein seed amplification assays.
Register here Learn more about StressMarq Biosciences
About this webinar
Parkinson’s disease (PD) is difficult to diagnose early, and symptoms often overlap with other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Alpha-synuclein seed amplification assays (SAAs), including RT-QuIC, have emerged as powerful tools that detect pathogenic alpha-synuclein aggregates with high sensitivity and specificity, helping to close this diagnostic gap.
In this session, Dr Laura Parkkinen, Professor of Translational Neuropathology and Director of the Oxford Brain Bank at the University of Oxford, will discuss the scientific basis, clinical relevance and future direction of SAAs, as well as their growing role in biomarker discovery and translational research in Parkinson’s disease and related disorders.
As SAA technology advances, improving assay robustness, scalability and reproducibility remains an important focus, closely linked to developments in recombinant substrate design. StressMarq Biosciences supports this progress through ongoing R&D efforts in collaboration with global experts.
Key topics
Participants will learn about:
Explain the scientific principles, workflow, and analytical sensitivity of alpha synuclein seed amplification assays (SAAs), including RT-QuIC.
Assess current limitations in SAA reproducibility, standardization, and scalability.
Evaluate the translational potential of SAA technology in precision diagnostics and biomarker development for neurodegenerative diseases.
Explore how innovation in recombinant protein design contributes to improved assay performance and reliability.
Speaker
Dr Laura Parkkinen
Professor of Translational Neuropathology & Director of the Oxford Brain Bank University of Oxford, United Kingdom
Related images
